Evonik has completed its first batch of Good Manufacturing Practice (GMP)-grade pharmaceutical lipids at its Lipid Innovation Center (LINC) in Lafayette, Indiana. This marks the start of production at the company’s expanded U.S. manufacturing operation, which is expected to reach full production capacity by mid-2027.
The new center, located at Evonik’s Tippecanoe site, aims to support domestic production of specialized pharmaceutical lipids used in advanced drug delivery systems. The project received support from the U.S. government to strengthen the country’s supply chain for materials used in next-generation medicines.
LINC is equipped to manufacture multiple lipid classes, accommodating various production processes and product requirements. Its output will support applications including cancer immunotherapies and gene therapies. The facility’s first product is PhytoChol, a cholesterol excipient used in lipid nanoparticle formulations, which are essential for nucleic acid-based therapeutics.
Evonik’s Indiana operation is part of a broader strategy to enhance its lipid-based drug delivery capabilities while complementing existing CDMO services. The facility will integrate with Evonik’s international pharmaceutical development and manufacturing network, facilitating the transition of processes to the company’s Birmingham, Alabama operations as programs advance.
Source: drug-dev.com · Image: Gov. Wolf Celebrates Job Creation with Ribbon Cutting for New Pharmaceutical Manufacturer in York County (51582005586) by Governor Tom Wolf from Harrisburg, PA, CC BY 2.0, via Wikimedia Commons
Get started today with Solo access →
